Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2024
0mins
Source: Globenewswire
Cingulate Inc. Overview: Cingulate Inc., a biopharmaceutical company, is advancing its Precision Timed Release™ (PTR™) drug delivery technology, focusing on ADHD treatment with its lead asset CTx-1301 and exploring other therapeutic areas.
Media Appearance: CEO Shane J. Schaffer discussed the company's plans for commercialization and future product candidates in an interview on the nationally syndicated Big Biz Show.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
